Table 3 Patients’ characteristics and treatment outcomes according to exposure to rituximab
CHT ± RT | R + CHT ± RT | |
|---|---|---|
Patients, n | 41 | 57 |
Male: female Stage I-II Stage III-IV B-symptoms LDH elevation SVC syndrome | 14: 27 28 (68.3%) 13 (31.7%) 21 (51.2%) 17 (41.5%) 23 (56.1%) | 26: 31 43 (75.4%) 14 (24.6%) 20 (35.1%) 8 (14.0%) 20 (35.1%) |
ORR CR PR SD PD | 97.6% 36 (87.8%) 4 (9.8%) 1 (2.4%) 0 | 84.2% 46 (80.7%) 2 (3.5%) 0 9 (15.8%) |
9 years OS 9 years DFS | 89.0% 83.2% | 83.1% 93.5% |